PainReform Says Its Supplier Of API Has Received A Deficiency Notice From The FDA Related To Its Drug Master File; Says Phase 3 Trial Is Expected To Commence Once Required Information Has Been Provided To FDA And Deficiency Notice Is Solved
Portfolio Pulse from Benzinga Newsdesk
PainReform's supplier of API has received a deficiency notice from the FDA related to its Drug Master File. The company's Phase 3 trial is expected to commence once the required information is provided to the FDA and the deficiency notice is resolved.
June 07, 2023 | 8:32 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
PainReform's stock may be affected by the FDA deficiency notice received by its API supplier, delaying the commencement of its Phase 3 trial.
The FDA deficiency notice received by PainReform's API supplier directly affects the company's ability to commence its Phase 3 trial. This delay may negatively impact investor sentiment and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100